Anergen, Novo Nordisk AG preclinical data

MG-AnergiX injected iv increased the survival rate of animals with induced clinical symptoms of experimental autoimmune MG to 67 percent, from 0-21 percent in the control group.

As published in Autoimmunity, treated animals had a marked improvement in disease state within three weeks of treatment, and remained stable for the duration of the one-year study. The drug was administered after the onset of early-stage symptoms. ...